Compare ENR & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | GLUE |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | 2021 |
| Metric | ENR | GLUE |
|---|---|---|
| Price | $20.46 | $18.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $25.00 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 1.3M | 881.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.56% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | $75,622,000.00 |
| Revenue This Year | $4.51 | $84.02 |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | ★ $6.48 | $72.42 |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $16.77 | $3.50 |
| 52 Week High | $31.78 | $25.77 |
| Indicator | ENR | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 44.78 |
| Support Level | $19.45 | $17.68 |
| Resistance Level | $20.92 | $18.66 |
| Average True Range (ATR) | 0.84 | 1.11 |
| MACD | -0.30 | -0.11 |
| Stochastic Oscillator | 2.05 | 43.12 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.